Trial Profile

Epigenetic Therapeutics to Overcome Resistance Against Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Proof-of-concept Clinical Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Geptanolimab (Primary) ; Zabinostat (Primary) ; Lenvatinib; Sorafenib
Indications Liver cancer
Focus Proof of concept; Therapeutic Use

Most Recent Events

26 Feb 2025 According to an Ingenex media release, data from this study were published in by investigators at The Lancet Summit on Cancer Control in China, recently held in Shanghai.
26 Feb 2025 Interim results published in an Ingenex Media Release.
21 Aug 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com